Upcoming event

Tags

5-α reductase inhibitors, Androgen antagonists, Article of the Month, ASCO GU21, ASCO GU22, ASCO21, AUA21, BCG, BCG therapy, BCG-unresponsive disease, Bladder neoplasms, Bladder-sparing therapy, Bladder-sparing trimodality, Chemoradiotherapy, Clinical pathways, Clinical staging, Collaborative care, Comorbidity, Cystectomy, Early recurrence patterns, EAU21, EAU22, EMUC21, EMUC22, EORTC, ERBB2, ERCC2, ESMO21, ESOU21, ESOU22, Gene expression analysis, Guidelines, Hematuria, High-risk NMIBC, Highlight of the Month, Immune checkpoint, Immune checkpoint blockade, Immunoregulation, Immunotherapy, Intravesical therapy, Laparoscopic radical cystectomy, Masterclass, Masterclass on MIBC, Masterclass on NMIBC, Meta-analysis, Metastatic urothelial cancer, MIBC, Microscopic haematuria, Molecular subtypes, Multiparametric MRI, Neoadjuvant, Neoadjuvant chemotherapy, Neoplasm recurrence, Nephroureterectomy, NIBC, Non-visible haematuria, Nuclear matrix protein 22, Oncologic outcomes, Open radical cystectomy, Optical coherence, PD-L1, Pembrolizumab, PET, PLND, Postoperative complications, POUT trial, Prevention & control, Quality of life, Radical cystectomy, Radio-chemotherapy, Randomized controlled trial, RARC, RAZOR Trial, Recurrence, Robotic, Robotic prostatectomy, Robotic radical cystectomy, Robotic surgery, Surgical video, Surgical videos, Systematic review, Tomography, Transitional cell, Transitional cell carcinoma, Tregs, Urinary bladder neoplasms, Urinary diversion, Urological surgery, Urothelial cancer, Urothelium, UROwebinar, UTUC, Webinar
Show all

DaBlaCa-13 Study: Oncological outcome of short-term, intensive chemoresection with mitomycin in nonmuscle invasive bladder cancer: Primary outcome of a randomized controlled trial

Journal of Clinical Oncology, October 2022

A randomized trial of PHOTOdynamic surgery in non–muscle-invasive bladder cancer

NEJM Evidence, September 2022

Chemoradiotherapy in muscle-invasive bladder cancer: 10-yr follow-up of the phase 3 randomised controlled BC2001 trial

European Urology, September 2022

Adjuvant intravesical chemohyperthermia versus passive chemotherapy in patients with intermediate-risk non-muscle-invasive bladder cancer (HIVEC-II): A phase 2, open-label, randomised controlled trial

European Urology, August 2022

Genomic biomarkers in peripheral blood (PB) from patients (pts) enrolled in the JAVELIN Bladder 100 trial of avelumab first-line (1L) maintenance in advanced urothelial carcinoma (aUC)

, September 2022

RACE IT: A prospective, single arm, multicenter, phase II-trial to assess safety and efficacy of preoperative RAdiation therapy before radical CystEctomy combined with ImmunoTherapy in locally advanced urothelial carcinoma of the bladder (AB 65/18) – first results

, September 2022

PD-L1 expression on immune cells by SP142 co-localises with dendritic cells and is associated with improved overall survival (OS) with atezolizumab in patients with untreated metastatic urothelial cancer (mUC)

, September 2022

First results from BladderPath: A randomised trial of MRI versus cystoscopic staging for newly diagnosed bladder cancer

, September 2022

Tumor and immune features associated with disease-free survival with adjuvant nivolumab in the phase III CheckMate 274 trial

, September 2022

Final results of neoadjuvant atezolizumab in cisplatin-ineligible patients with muscle-invasive urothelial cancer of the bladder

European Urology, August 2022

Non-muscle invasive bladder cancer subtypes with differential response to intravesical bacillus Calmette-Guerin treatment

[18F]-FDG PET/CT for bladder cancer staging and decision-making in patients with High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC)

Next